{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xue X"],"funding":["National Natural Science Foundation of China","China Postdoctoral Science Foundation"],"pagination":["nwaa286"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8433091"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["8(9)"],"pubmed_abstract":["Synthetic lethality was proposed nearly a century ago by geneticists and recently applied to develop precision anti-cancer therapies. To exploit the synthetic lethality concept in the design of chemical anti-cancer agents, we developed a bio-orthogonally catalyzed lethality (BCL) strategy to generate targeting anti-tumor metallodrugs both <i>in vitro</i> and <i>in vivo.</i> Metallodrug Ru-rhein was generated from two non-toxic species Ru-N<sub>3</sub> and rhein-alkyne via exclusive endogenous copper-catalyzed azide alkyne cycloaddition (CuAAC) reaction without the need of an external copper catalyst. The non-toxic species Ru-arene complex Ru-N<sub>3</sub> and rhein-alkyne were designed to perform this strategy, and the mitochondrial targeting product Ru-rhein was generated in high yield (>"],"journal":["National science review"],"pubmed_title":["Using bio-orthogonally catalyzed lethality strategy to generate mitochondria-targeting anti-tumor metallodrugs <i>in vitro</i> and <i>in vivo</i>."],"pmcid":["PMC8433091"],"funding_grant_id":["22025701","21731004","21807060","2019M651874","22077066","21771109","21420102002"],"pubmed_authors":["Lv M","Qian Y","Guo Z","Qian C","Liu HK","Dong J","Su Z","Zhao J","Xue X","Tao Q","Dai Y"],"additional_accession":[]},"is_claimable":false,"name":"Using bio-orthogonally catalyzed lethality strategy to generate mitochondria-targeting anti-tumor metallodrugs <i>in vitro</i> and <i>in vivo</i>.","description":"Synthetic lethality was proposed nearly a century ago by geneticists and recently applied to develop precision anti-cancer therapies. To exploit the synthetic lethality concept in the design of chemical anti-cancer agents, we developed a bio-orthogonally catalyzed lethality (BCL) strategy to generate targeting anti-tumor metallodrugs both <i>in vitro</i> and <i>in vivo.</i> Metallodrug Ru-rhein was generated from two non-toxic species Ru-N<sub>3</sub> and rhein-alkyne via exclusive endogenous copper-catalyzed azide alkyne cycloaddition (CuAAC) reaction without the need of an external copper catalyst. The non-toxic species Ru-arene complex Ru-N<sub>3</sub> and rhein-alkyne were designed to perform this strategy, and the mitochondrial targeting product Ru-rhein was generated in high yield (>","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Sep","modification":"2025-05-29T20:47:18.978Z","creation":"2025-05-29T20:47:18.978Z"},"accession":"S-EPMC8433091","cross_references":{"pubmed":["34691728"],"doi":["10.1093/nsr/nwaa286"]}}